NCT07532265

A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma Not Adequately Controlled With Medium to High Dose ICS/LABA

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 512 (estimated)
• Sponsor: Kinaset Therapeutics Inc · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Detailed description

A Phase 2 Randomized Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Three Doses of Frevecitinib (KN-002) in Patients With Severe Asthma Not Adequately Controlled With Medium to High Dose ICS/LABA Therapy

Conditions

• Severe Asthma

Interventions

Type	Name	Description
DRUG	Frevecitinib	Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)
DRUG	Placebo	Matching placebo to frevecitinib

Timeline

• Start date: 2026-06-01
• Primary completion: 2027-11-30
• Completion: 2027-11-30
• First posted: 2026-04-15
• Last updated: 2026-04-15

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study